-
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Not Recruiting
More
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic
T-cell lymphoma.
PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients
with recurrent or refractory angioimmunoblastic T-cell lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office, 6504987061.
Stanford Investigators
View full details
-
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Cisplatin may also make tumor
cells more sensitive to radiation therapy. Monoclonal antibodies, such as cetuximab, can
block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Giving radiation therapy and cisplatin together with cetuximab may kill more tumor cells. It
is not yet known whether radiation therapy and cisplatin are more effective with or without
cetuximab in treating head and neck cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy, cisplatin, and
cetuximab to see how well they work compared to radiation therapy and cisplatin in treating
patients with stage III or stage IV head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Trevor Elizabeth Krakow, 6507254777.
Stanford Investigators
View full details
-
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving rituximab together with combination chemotherapy may kill more
cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination
chemotherapy works in treating patients with stage II, stage III, or stage IV diffuse large
B-cell non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
This randomized phase III trial studies chemotherapy to see how well it works with or without
bevacizumab in treating patients with head and neck squamous cell carcinoma that has come
back (recurrent) or that has spread to other parts of the body (metastatic). Drugs used in
chemotherapy, such as docetaxel, cisplatin, carboplatin, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may
interfere with the ability of tumor cells to grow and spread. Bevacizumab may also make tumor
cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking
blood flow to the tumor. It is not yet known whether combination chemotherapy is more
effective when given with or without bevacizumab in treating patients with head and neck
squamous cell carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Wong, 650-723-1002.
Stanford Investigators
View full details
-
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Recruiting
More
The purpose of this study is to identify and confirm new blood and tissue markers for
prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has
been shown to increase the risk of tumor spread and enhance tumor resistance to the standard
treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently
identified several proteins or markers in the blood and in tumors (including osteopontin,
lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that
may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
Lead Sponsor
Stanford Investigators
View full details
-
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Not Recruiting
More
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic
differentiated thyroid cancer refractory to radioiodine
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Not Recruiting
More
This randomized phase II trial studies azacitidine with or without entinostat to see how well
they work compared to azacitidine alone in treating patients with myelodysplastic syndromes,
chronic myelomonocytic leukemia, or acute myeloid leukemia. Drugs used in chemotherapy, such
as azacitidine, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Entinostat may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving azacitidine together with entinostat may work better in treating patients with
myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mai Tran, 6507238594.
Stanford Investigators
View full details
-
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Not Recruiting
More
This phase II, open-label, randomized study will evaluate the efficacy and safety of
MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of
the head and neck who have progressed during or following platinum-based chemotherapy.
Patients will be randomized to receive either MEHD7945A 1100 mg intravenously (iv) every 2
weeks or cetuximab 400 mg/m2 iv loading dose followed by 250 mg/m2 iv weekly. Patients
treated with cetuximab (Arm B) may cross-over to MEHD7945A (Arm A) upon central confirmation
of progressive disease and upon meeting eligibility criteria. Anticipated time on study
treatment is until disease progression or intolerable toxicity occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Not Recruiting
More
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and
paclitaxel to see how well they work with or without bevacizumab in treating patients with
cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread
to the lymph nodes but is at high risk for returning (high-risk, lymph node-negative breast
cancer). Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal
antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and
spread. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the
tumor. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery
and help prevent the tumor from returning. It is not yet known whether doxorubicin
hydrochloride, cyclophosphamide, and paclitaxel are more effective with or without
bevacizumab.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pei-Jen Chang, 6507250866.
Stanford Investigators
View full details
-
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from
dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either
kill them or deliver radioactive tumor-killing substances to them without harming normal
cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is
more effective in treating non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given
together with combination chemotherapy to see how well they work in treating patients with
newly-diagnosed non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. It is not yet known if selenium is effective in
preventing the growth of new tumors in patients with previously resected non-small cell lung
cancer.
PURPOSE: This randomized phase III trial is studying selenium to see how well it works
compared to a placebo in preventing the development of second primary lung tumors in patients
who have undergone surgery to remove stage I non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nancy Mori, 6507240201.
Stanford Investigators
View full details
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Not Recruiting
More
This randomized phase II trial is studying how well giving ipilimumab with or without
sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that
cannot be removed by surgery (unresectable). Ipilimumab works by activating the patient's
immune system to fight cancer. Colony-stimulating factors, such as sargramostim, may increase
the number of immune cells found in bone marrow or peripheral blood and may help the immune
system recover from the side effects of treatment. It is not yet known whether giving
ipilimumab together with sargramostim is more effective than ipilimumab alone in treating
melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Vani Jain, 6507255459.
Stanford Investigators
View full details
-
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Not Recruiting
More
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2
Regimen in patients with untreated, resectable squamous cell cancer of the head and neck
(HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Not Recruiting
More
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known
whether treatment with interferon alfa is more effective than observation alone for stage II
or stage III melanoma that has been completely removed surgically.
PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how
well it works compared to observation only in treating patients with stage II or stage III
melanoma that has been completely removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sunil Arani Reddy, 6507361234.
Stanford Investigators
View full details
-
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in
vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different
human tumor types including colon, pancreatic, lung, and ovarian. This activity was
cytostatic in nature and was maintained if dosing was continued. That is, tumor growth is
suspended while the drug is administered but returns to baseline rates when the agent is
withdrawn. Therefore, the optimal schedule will be an uninterrupted one. To assess the
activity of sorafenib in a timely manner and with a meaningful interpretation, a randomized
discontinuation design was adopted in the present trial, conducted in a population who were
potentially sensitive to sorafenib.
PURPOSE: This randomized phase II trial is studying sorafenib to see how well it works
compared to placebo in treating patients with refractory non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
Not Recruiting
More
To see if a limited sampling of tumor tissue from human subjects is a feasible way to gather
adequate tissue for cancer stem cell quantification.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Lead Sponsor
Stanford Investigators
View full details
-
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Not Recruiting
More
This phase II trial is studying how well sorafenib works in treating patients with recurrent
diffuse large B-cell non-Hodgkin's lymphoma. Sorafenib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Daadi, 6507256456.
Stanford Investigators
View full details
-
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Not Recruiting
More
This randomized phase III trial studies ipilimumab to see how well it works compared to
high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that
has been removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Interferon alfa-2b may interfere with the growth of tumor
cells and slow the growth of melanoma and other cancers. It is not yet known whether
ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 650-725-0426.
Stanford Investigators
View full details
-
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
Not Recruiting
More
This phase II trial is studying how well giving rituximab together with combination
chemotherapy and 90-Yttrium ibritumomab tiuxetan works in treating patients with stage I or
stage II lymphoma. Drugs used in chemotherapy, such as prednisone, cyclophosphamide,
doxorubicin, and vincristine, work in different ways to stop cancer cells from dividing so
they stop growing or die. Monoclonal antibodies such as rituximab and yttrium 90-Yttrium
ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive
cancer-killing substances to them without harming normal cells. Combining a monoclonal
antibody with combination chemotherapy and a radiolabeled monoclonal antibody may kill more
cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office, 6504987061.
Stanford Investigators
View full details
-
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Not Recruiting
More
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to
help focus thin beams of radiation directly on the tumor, and giving radiation therapy in
higher doses over a shorter period of time, may kill more tumor cells and have fewer side
effects. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. It is not yet known whether radiation
therapy is more effective when given alone or together with cetuximab in treating patients
with head and neck cancer that has been removed by surgery.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it
works compared with radiation therapy given together with cetuximab in treating patients who
have undergone surgery for locally advanced head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alice Banh, 650-723-1423.
Stanford Investigators
View full details
-
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Not Recruiting
More
This randomized phase III trial studies sunitinib malate to see how well it works compared to
sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed
by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that
remain after surgery. It is not yet known whether sunitinib malate is more effective than
sorafenib tosylate or placebo in treating kidney cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Denise Haas, 6507361252.
Stanford Investigators
View full details
-
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the
growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving bevacizumab together with combination chemotherapy may
kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with several
chemotherapy drugs (combination chemotherapy) works in treating patients with peripheral
T-cell lymphoma or natural killer cell neoplasms.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Not Recruiting
More
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells
from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by
blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill
more tumor cells. It is not yet known whether docetaxel is more effective with or without
gefitinib in treating head and neck cancer. This randomized phase III trial is studying
docetaxel and gefitinib to see how well they work compared to docetaxel alone in treating
patients with metastatic or locally recurrent head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dimitrios Colevas, 6507249707.
Stanford Investigators
View full details
-
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. It is not yet
known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and
comparing them to see how well they work in treating patients with low tumor burden indolent
stage III non-Hodgkin's lymphoma or stage IV non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office, 6504987061.
Stanford Investigators
View full details
-
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
Not Recruiting
More
This study is being conducted to determine the best confirmed response rate, safety, and
tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the
head and neck (SCCHN). GSK1363089 is a new chemical entity that inhibits multiple receptor
tyrosine kinases (RTKs) with growth-promoting and angiogenic properties. The primary targets
of GSK1363089 are the HGF and vascular endothelial growth factor (VEGF) RTK families (eg,
MET, VEGFR2/kinase insert domain receptor [KDR]). Since MET overexpression has been
associated with poorer prognosis and MET tyrosine kinase mutations have been reported in
SCCHN, inhibition of MET receptor and VEGFR2/KDR activation by agents such as GSK1363089 may
be of therapeutic benefit in this patient population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Not Recruiting
More
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill
tumor cells.
PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma
peptides from cytotoxic T cells and helper T cells to see how well they work in treating
patients with metastatic melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sunil Arani Reddy, 6507361234.
Stanford Investigators
View full details
-
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
Not Recruiting
More
This Phase II, multicenter, randomized, double-blind, placebo-controlled trial was designed
to estimate the efficacy and characterize the safety of bevacizumab when combined with
carboplatin + paclitaxel chemotherapy compared with carboplatin + paclitaxel chemotherapy
alone in patients with previously untreated metastatic melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sunil Arani Reddy, 6507361234.
Stanford Investigators
View full details
-
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by
radiation therapy and chemotherapy in treating patients who have stage III or stage IV cancer
of the larynx or stage III or stage IV cancer of the oropharynx.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nancy Mori, 6507240201.
Stanford Investigators
View full details
-
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Not Recruiting
More
The purpose of this research study is to test the safety and effectiveness of palifermin to
determine if weekly doses can be safely administered to reduce the incidence (occurrence of),
duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in
the mouth). Mucositis is a common side effect for patients receiving chemotherapy
(cancer-killing drug) and radiotherapy (cancer-killing x-rays) for the treatment of head and
neck cancer (HNC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Rachel Freiberg, 6507254777.
Stanford Investigators
View full details
-
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Not Recruiting
More
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with
locally advanced or metastatic mucosal melanoma or acral melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Wong, 650-723-1002.
Stanford Investigators
View full details
-
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Not Recruiting
More
This phase II trial is studying how well giving rituximab together with combination
chemotherapy and bortezomib works in treating patients with untreated mantle cell lymphoma.
Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin, vincristine, and dexamethasone, work in different ways to stop
the growth of cancer cells, either by killing the cells or stopping them from dividing.
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving rituximab together with combination chemotherapy and bortezomib may kill
more cancer cells.
Treatment consists of six agents: bortezomib (Vc), rituximab (R), cyclophosphamide (C),
vincristine (V), doxorubicin (A), and dexamethasone (D) (VcR-CVAD).
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Not Recruiting
More
The purpose of this research study is to evaluate the progression-free survival (PFS) with
XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally
advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to
receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits
VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
The Clinical Steering Committee for this study, comprised of study doctors who specialize in
medullary thyroid cancer, has provided guidance regarding the design of the study. The
committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven
Sherman, MD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Not Recruiting
More
Docetaxel and cetuximab are FDA-approved for the treatment of squamous cell carcinoma of the
head and neck (SCCHN). Cisplatin and carboplatin, while not FDA-approved for SCCHN, have been
used as standard of care in SCCHN patients in combination with other drugs. This study
evaluates if weekly cisplatin and docetaxel, in combination with cetuximab, is effective in
palliative treatment of patients with SCCHN. These drugs will be given intravenously weekly,
repeated 3 of every 4 weeks until evidence of disease progression or unacceptable adverse
events.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Not Recruiting
More
This phase I trial studies how well talactoferrin works in treating patients with relapsed or
refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
Biological therapies, such as talactoferrin, may stimulate the immune system in different
ways and stop tumor cells from growing
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Lead Sponsor
Stanford Investigators
View full details
-
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others
interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy,
such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine,
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving rituximab together with combination chemotherapy may kill
more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination
chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Not Recruiting
More
This randomized phase III trial studies chemotherapy and bevacizumab to see how well they
work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage
IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving more than one drug
(combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab
also may stop the growth of non-small cell lung cancer by blocking the growth of new blood
vessels necessary for tumor growth. It is not yet known whether chemotherapy is more
effective with or without bevacizumab in treating non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Not Recruiting
More
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA
concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients
with nasopharyngeal carcinoma (NPC).
2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these
tumors both in endemic and non-endemic areas.
3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for
both endemic and non-endemic patient populations.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 650-498-6184.
Lead Sponsor
Stanford Investigators
View full details
-
BIBW 2992 (Afatinib) in Head & Neck Cancer
Not Recruiting
More
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with
cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after
failure of platinum-containing therapy. In addition, the trial aims to clarify the influence
of EGFR genotype on tumor response to the treatment regimens.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Not Recruiting
More
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206
works in treating patients with previously treated prostate cancer. Androgens can cause the
growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the
amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. It is not yet known whether
bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 650-725-0426.
Stanford Investigators
View full details
-
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Not Recruiting
More
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck
cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the
efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression
(TTP) in this group of patients. In addition, we will determine the 2-year locoregional
control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these
patients. We will also evaluate the profile and frequency of late toxicity, specifically
mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with
locally advanced head and neck squamous cell carcinoma (HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Brian Khong, 6507254777.
Stanford Investigators
View full details
-
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Radiation therapy uses high energy
x-rays to kill tumor cells. Giving paclitaxel, cisplatin, and cetuximab together with
radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying paclitaxel, cisplatin, and cetuximab to see how well
they work when followed by cetuximab and two different doses of intensity-modulated radiation
therapy in treating patients with HPV-associated stage III or stage IV cancer of the
oropharynx that can be removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
Not Recruiting
More
The primary objective of the study is to provide treatment with Ipilimumab to subjects who
have serious or immediately life-threatening unresectable Stage III or Stage IV melanoma, who
have no alternative treatment options, and whose physicians believe, based upon available
data on benefit and risk, that it is appropriate to administer Ipilimumab at a dose of 3
mg/kg induction (with re-induction, if eligible), or for eligible subjects previously
enrolled in Ipilimumab studies CA184-042, CA184-078, CA184-087, MDX010-16, or MDX010-20.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sunil Arani Reddy, 6507361234.
Stanford Investigators
View full details
-
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Not Recruiting
More
This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to
see how well they work compared to carboplatin and paclitaxel in treating patients with stage
III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such
as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor. It is not yet known whether giving carboplatin and
paclitaxel together with sorafenib tosylate is more effective than carboplatin and paclitaxel
in treating melanoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sunil Reddy, 6507361234.
Stanford Investigators
View full details
-
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
Not Recruiting
More
To determine safety profile of the epidermal growth factor receptor (EGFR) antagonist, ZD1839
in combination with cisplatin and radiation therapy in patients with local-regional recurrent
squamous cell cancer of the head and neck.
To study the effects of ZD1839 combined with either cisplatin or radiotherapy on signal
transduction pathway gene expression in tumor cells in patients with local-regional recurrent
squamous cell cancer of the head and neck using micro array analysis from tumor samples taken
at the time of relapse and during treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Priscilla Wong, 6507254777.
Lead Sponsor
Stanford Investigators
View full details
-
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Not Recruiting
More
This randomized phase III trial studies oxaliplatin, leucovorin calcium, fluorouracil, and
bevacizumab to see how well they work compared to oxaliplatin, leucovorin calcium, and
fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs
used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet
known whether giving combination chemotherapy together with bevacizumab is more effective
than combination chemotherapy alone in treating colon cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nancy Mori, 6507240201.
Stanford Investigators
View full details
